NO20002412L - Method of treating tumors and tumor cells using ex vivo activated T cells - Google Patents

Method of treating tumors and tumor cells using ex vivo activated T cells

Info

Publication number
NO20002412L
NO20002412L NO20002412A NO20002412A NO20002412L NO 20002412 L NO20002412 L NO 20002412L NO 20002412 A NO20002412 A NO 20002412A NO 20002412 A NO20002412 A NO 20002412A NO 20002412 L NO20002412 L NO 20002412L
Authority
NO
Norway
Prior art keywords
cells
treating tumors
vivo activated
tumor cells
vivo
Prior art date
Application number
NO20002412A
Other languages
Norwegian (no)
Other versions
NO20002412D0 (en
Inventor
David N Liebowitz
Carl June
Original Assignee
Arch Dev Corp
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp, Jackson H M Found Military Med filed Critical Arch Dev Corp
Publication of NO20002412D0 publication Critical patent/NO20002412D0/en
Publication of NO20002412L publication Critical patent/NO20002412L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er tilveiebrakt nye fremgangsmåter for modulering av en immunrespons ved anvendelse av behandling med T-celler som behandles ex vivo. Oppfinnelsen tilveiebringer en løsning på problemene som angår behandling av forskjellige sykdommer, spesielt sykdommer med malign beskaffenhet. Oppfinnelsen tilveie- bringer dessuten fremgangsmåter for behandling av sykdommer av ikke-malign beskaffenhet, ved modulering av et pattedyrs immunrespons.New methods have been provided for modulating an immune response using treatment with T cells treated ex vivo. The invention provides a solution to the problems related to the treatment of various diseases, especially diseases of a malignant nature. The invention further provides methods for treating diseases of non-malignant nature by modulating a mammalian immune response.

NO20002412A 1997-11-10 2000-05-09 Method of treating tumors and tumor cells using ex vivo activated T cells NO20002412L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6503197P 1997-11-10 1997-11-10
PCT/US1998/023954 WO1999024045A1 (en) 1997-11-10 1998-11-10 Methods for treatment of tumors and tumor cells using ex vivo activated t cells

Publications (2)

Publication Number Publication Date
NO20002412D0 NO20002412D0 (en) 2000-05-09
NO20002412L true NO20002412L (en) 2000-07-07

Family

ID=22059894

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002412A NO20002412L (en) 1997-11-10 2000-05-09 Method of treating tumors and tumor cells using ex vivo activated T cells

Country Status (6)

Country Link
EP (1) EP1030674A1 (en)
JP (1) JP2001522806A (en)
AU (1) AU1395499A (en)
CA (1) CA2309206A1 (en)
NO (1) NO20002412L (en)
WO (1) WO1999024045A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
CA2525519A1 (en) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
JP2007525225A (en) 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド Method for preparing T cells for cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
JP2010032444A (en) * 2008-07-30 2010-02-12 Olympus Corp Living tissue treatment device
CA2838046C (en) 2011-05-03 2023-03-07 Immunovative Therapies, Ltd. Induction of il-12 using immunotherapy
CN108261423B (en) 2011-05-03 2021-01-08 免疫创新治疗有限公司 Method for processing biological medicine containing living cells
JP6994021B2 (en) 2016-08-26 2022-01-14 ジュノー セラピューティクス インコーポレイテッド How to count the particles present in a cell composition
PL3644728T3 (en) 2017-06-28 2022-12-05 Sci-Group As Freezing of biological material
EP3759490A1 (en) * 2018-02-28 2021-01-06 Juno Therapeutics, Inc. Methods for detecting particles present in a cell composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE873057L (en) * 1986-11-13 1988-05-13 Tretorn Ab Compositions and method for treatment of cancer using¹monoclonal antibody against gd3 ganglioside together eith¹il-2
EP1488805A2 (en) * 1992-04-07 2004-12-22 The Regents of the University of Michigan CD28 pathway immunoregulation
PT700430E (en) * 1993-06-04 2005-07-29 Univ Michigan PROCESS FOR SELECTIVELY STIMULATING T-CELL PROLIFERATION
WO1997005239A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease

Also Published As

Publication number Publication date
CA2309206A1 (en) 1999-05-20
WO1999024045A1 (en) 1999-05-20
NO20002412D0 (en) 2000-05-09
AU1395499A (en) 1999-05-31
JP2001522806A (en) 2001-11-20
EP1030674A1 (en) 2000-08-30

Similar Documents

Publication Publication Date Title
NO20002412L (en) Method of treating tumors and tumor cells using ex vivo activated T cells
DK0986382T3 (en) RAF kinase inhibitors
NO974275L (en) Method of treating tumors
DE69830072D1 (en) RADIOACTIVE COMPOSITIONS FOR THE TREATMENT OF PROSTATE TUMORS
EA199800391A1 (en) Inhibition of tumor growth by antisense oligonucleotides to IL-8 and IL-8 receptor
GB2344532A (en) Electromagnetic radiation therapy
MY121548A (en) Compounds and methods for the treatment of cancer
ATE378014T1 (en) SYSTEM FOR TREATING ABNORMAL TISSUE IN THE HUMAN ESOPHAUS
EA200100573A1 (en) APPLICATION OF CYCLOOXIGENASE-2 INHIBITOR, MATRIC METALLOPROTEINASE INHIBITOR, ANTI-TUMOR MEDICINE, AND OPTIONAL IRRADIATION AS A COMBINED METHOD OF TREATING THE NEO.
ATE260666T1 (en) CELLULAR VACCINE AND USE THEREOF FOR THE TREATMENT OF MALIGNANT SOLID TUMORS
ATE258796T1 (en) USE OF VITAMIN D4 DERIVATIVES TO TREAT SKIN DISEASES
ES2118414T3 (en) USE OF INDOLOCARBAZOL DERIVATIVES FOR THE TREATMENT OF PROSTATE.
NO974824L (en) Arteriovenous and venous transplant treatments, procedures and mixtures
DK0912192T3 (en) Administration of GM-CSF to treat brain tumors and prevent the recurrence of such tumors
NO20000752L (en) Method of preventing or treating estrogen-dependent diseases and disorders
ATE402713T1 (en) GENETICALLY MANIPULATED HERPES VIRUSES FOR THE TREATMENT OF TUMORS
NO965395L (en) Human monoclonal antibodies specific for cell cycle-independent glioma surface antigen
ES2187648T3 (en) METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY.
EA200300525A1 (en) Glycosidation of indolcarbazole using interphase catalysis
ATE392210T1 (en) METHODS OF TREATING SOLID TUMORS AND METASTASIS USING GENE THERAPY
DE60044350D1 (en) PROSTATE SPECIFIC GEN PCGEM1 AND METHODS OF USE FOR THE RECOGNITION, TREATMENT AND PREVENTION OF PROSTATE CANCER
DE3856329D1 (en) Use of Ethisterone for topical treatment of acne or androgenetic alopecia
ATE251462T1 (en) METHOD FOR TREATING SCAR TISSUE
Karu et al. Biological action of low-intensity monochromatic light in the visible range
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application